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Idiopathic pulmonary fibrosis (IPF) is a progressive
and typically fatal lung disease. To gain insight into
the pathogenesis of IPF, we reanalyzed our previously
published gene expression data profiling IPF lungs.
Cytokine receptor-like factor 1 (CRLF1) was among
the most highly up-regulated genes in IPF lungs, com-
pared with normal controls. The protein product
(CLF-1) and its partner, cardiotrophin-like cytokine
(CLC), function as members of the interleukin 6 (IL-6)
family of cytokines. Because of earlier work implicat-
ing IL-6 family members in IPF pathogenesis, we
tested whether CLF-1 expression contributes to in-
flammation in experimental pulmonary fibrosis. In
IPF, we detected CLF-1 expression in both type II al-
veolar epithelial cells and macrophages. We found
that the receptor for CLF-1/CLC signaling, ciliary neu-
rotrophic factor receptor (CNTFR), was expressed
only in type II alveolar epithelial cells. Administration
of CLF-1/CLC to both uninjured and bleomycin-in-
jured mice led to the pulmonary accumulation of
CD4 T cells. We also found that CLF-1/CLC adminis-
tration increased inflammation but decreased pulmo-
nary fibrosis. CLF-1/CLC leads to significantly en-
riched expression of T-cell-derived chemokines and
cytokines, including the antifibrotic cytokine inter-feron-. We propose that, in IPF, CLF-1 is a selective
stimulus of type II alveolar epithelial cells and may
potentially drive an antifibrotic response by augment-
ing both T-helper-1-driven and T-regulatory-cell-driven
inflammatory responses in the lung. (Am J Pathol 2012,
180:1963–1978; DOI: 10.1016/j.ajpath.2012.01.010)
Idiopathic pulmonary fibrosis (IPF) is a progressive dis-
order characterized by unrelenting accumulation of myo-
fibroblasts and by deposition of collagens in the lower
respiratory tract, leading ultimately to breathlessness and
respiratory failure. It is a rare disease, with an estimated
prevalence of 14 to 43 per 100,000 people, depending
on the case definition of IPF.1 The disease is typically
discovered late in its course, and the median survival
time is close to 3 years from the time of diagnosis.2
Except for lung transplantation, in the United States, there
are no approved therapies for IPF.
Although anti-inflammatory or immunologically active
agents have proven ineffective in IPF,3–5 studies in cyto-
kine signaling in both IPF and animal models of fibrosis
still provide a strong rationale for investigating inflamma-
tory pathways in IPF. The dichotomy between cytokines
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AJP May 2012, Vol. 180, No. 5elaborated by type 1 helper T cells (Th1) and type 2
helper T cells (Th2) has been studied in IPF3,6,7 and in
animal models of fibrosis. The Th1 cytokine interferon-
(IFN-) suppresses fibroblast proliferation and collagen
synthesis8–10 and tends to attenuate fibrosis in animal
models.10–12 In contrast, the Th2 cytokines interleukins 4
and 13 (IL-4 and IL-13) promote fibroblast proliferation13
and have been shown to augment pulmonary fibro-
sis.14,15 The proinflammatory molecule IL-6 and its family
members have also been implicated in the pathogenesis
of IPF as a factor promoting the growth and survival of
human lung fibroblasts in vitro16–18 and lung injury and
fibrosis in animal models.19,20
To study IPF, a disease that is shaped by a complex
interplay of genetic,21–23 epigenetic,24–26 and environ-
mental27–29 factors, we and others have used gene ex-
pression profiling technologies to identify both individual
genes and networks of genes that may contribute to the
pathogenesis of IPF.30–33 Because of the roles that
growth factor and cytokine signaling pathways likely play
in the pathogenesis of both IPF and experimental pulmo-
nary fibrosis, we re-examined our gene expression pro-
filing data comparing IPF lungs and normal controls,33 to
identify genes involved in growth factor and cytokine
signaling pathways. Our reanalysis revealed significantly
increased expression of the secreted receptor cytokine-
like factor 1 (CLF-1; also known as cytokine receptor-like
factor 1 and encoded by the CRLF1 gene). CLF-1 is
secreted as a heterodimer with cardiotrophin-like cyto-
kine (CLC), a member of the IL-6 family of cytokines.34
The functions of CLF-1 in the lung and in pulmonary
fibrosis are unknown. From our gene expression data,
CLF-1 was the most highly up-regulated member of the
IL-6 family. Thus, we reasoned that CLF-1 may play an
analogous role to IL-6 in the lung potentiating injury,
inflammation, and fibroproliferation. We therefore investi-
gated the expression pattern of CLF-1 in IPF and deter-
mined the role of CLF-1 in an experimental model of
pulmonary fibrosis.
Materials and Methods
The studies were approved by the Institutional Review
Boards and Institutional Animal Care and Use Commit-
tees of Columbia University and the University of Pitts-
burgh.
Reagents
The Sircol collagen assay was from Biocolor (Belfast,
UK). Recombinant human CLF-1/CLC, and antibodies
directed against leukemia inhibitory factor receptor-
(LIFR) and CNTFR were from R&D Systems (Minneap-
olis, MN). Pentobarbital solution was from the Henry
Schein company (Melville, NY). Bleomycin and leukemia
inhibitory factor (LIF) were from Sigma-Aldrich (St. Louis,
MO). Antibodies against mouse B220 (clone RA3-6B2),
CD3 (clone 145-2C11), CD8 (clone YTS105.18), CD68
(clone FA-11), mouse neutrophils (clone 7/4), and human
CD68 (clone Ki-M7) were obtained from AbD Serotec(Raleigh, NC). Rat IgG directed against mouse CD4
(clone RM4-5) and mouse Foxp3 (clone NRRF-30) were
from eBioscience (San Diego, CA). Rabbit IgG against
phosphorylated Stat3 (clone D3A7) and total Stat3 were
from Cell Signaling Technology (Danvers, MA). Rabbit
antibody against surfactant protein C (SP-C) was ob-
tained from Seven Hills Bioreagents (Cincinnati, OH).
Goat anti-rabbit Fab fragments, peroxidase-, rhodamine-,
and Cy5-conjugated secondary antibodies, Cy5-conju-
gated streptavidin, nonimmune rabbit and goat IgG were
from Jackson ImmunoResearch (West Grove, PA). Pierce
SuperSignal West Pico Chemiluminescent substrate was
from Thermo Fisher Scientific (Rockford, IL). Vectastain
ABC universal kit, 3,3=-diaminobenzidine, Vector SG sub-
strate, aminoethylcarbazole, and Gill’s hematoxylin were
from Vector Laboratories (Burlingame, CA). Rabbit IgG
against Tbet, Power SYBR Green, high-capacity reverse
transcriptase, and a one-step RT-PCR kit were from Life
Technologies-Invitrogen (Carlsbad, CA) and Life Tech-
nologies-Applied Biosystems (Foster City, CA). Elastase
was from Worthington Biochemical (Lakewood, NJ).
Gene Expression Profiling of mRNA From
Human Lung Tissue
The details of our gene expression profiling experiment
have been reported previously.33 In brief, RNA was ex-
tracted from whole-lung homogenates from patients with
IPF and from normal control subjects. Hybridization of
biotinylated cRNA was performed on a human genome
U95Av2 array (Affymetrix, Santa Clara, CA). Data were
analyzed with GeneSpring software versions 5.0 (Agi-
lent Technologies, Santa Clara, CA), followed by a
supervised analysis using open-source Cluster and
TreeView software version 1.60 (http://rana.lbl.gov/
EisenSoftware.htm).
RNA Extraction for RT-PCR of Human Tissue
Total RNA was extracted from 30 to 50 g of snap-
frozen lung tissue collected by the Lung Tissue Re-
search Consortium (stored at the University of Colo-
rado, Denver, CO) from 49 normal lung histology
control subjects and 50 IPF patients. RNA was pro-
cessed by tissue homogenization and disruption with
an electric homogenizer (PolyTron homogenizer
H3660-2A; Kinematica, Lucerne, Switzerland) in 700
L of QIAzol lysis reagent (Qiagen, Valencia, CA) ac-
cording to the manufacturer’s instructions. RNA was
further purified using a miRNeasy mini kit (217004;
Qiagen) with a QIAcube automated system (9001292;
Qiagen). The purity of the RNA was verified spectro-
scopically, and the quality of the RNA was assessed
using an Agilent 2100 bioanalyzer.
Quantitative RT-PCR of mRNA from Human
Tissue
Quantitative RT-PCR was performed using the ABI TaqMan
system (Life Technologies) to validate the gene expres-
ed, pa
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ated with a TaqMan RNA-to-CT one-step kit (including
master mix containing AmpliTaq Gold DNA polymerase,
UTP, dNTPs, and buffers) according to the manufactur-
er’s protocol. The PCR conditions were as follows: 15
minutes at 48°C, 12 minutes at 95°C, and then 40 cycles
with 15 seconds at 95°C and 1 minute at 60°C in an ABI
7300 real-time PCR system (Life Technologies). PPIA
[peptidylprolyl isomerase A (cyclophilin A)] was used as
the housekeeping gene for normalization.
Isolation and Use of Primary Rat Type II Alveolar
Epithelial Cells
Primary rat type II alveolar epithelial cells were isolated
by elastase-mediated digestion of uninjured lungs from
Sprague-Dawley rats (Harlan Sprague-Dawley, Indianap-
olis, IN), as described previously.35 Cells were plated in
Dulbecco’s modified Eagle’s medium  10% fetal bovine
serum, followed by serum starvation and stimulation with
recombinant human (rh) CLF-1/CLC at 25 ng/mL for up to
60 minutes. Cells were lysed in radioimmunoprecipitation
assay buffer with 0.1% SDS, protease inhibitors, and
sodium orthovanadate. Lysates were processed for im-
munoblotting for phosphorylated Stat3 (p-Stat3). Im-
munoblots were then stripped and reprobed for total
Stat3. Quantitative densitometry was performed using
ImageJ software version 1.4.3.67 (NIH, Bethesda, MD),
as described previously.36
Delivery of rhCLF-1/CLC to Mice
Cell culture grade, recombinant human CLF-1/CLC was
purchased from R&D Systems (Minneapolis, MN). CLF-
1/CLC was resuspended according to the recommenda-
tions of the manufacturer in hydrochloric acid 4 mmol/L
0.1% bovine serum albumin. For delivery to the animal, 2
Table 1. Antibodies and Staining Conditions for Immunohistoch
Lung
tissue Fixation method Antigen retrieval
Rat FFPE Sodium citrate, 10 mmol/L,
pH 6.8
Mouse FFPE EDTA, 1 mmol/L, pH 8
Mouse FFPE EDTA, 1 mmol/L, pH 8
Mouse FFPE Sodium citrate 10 mmol/L,
pH 6.8
Mouse FFPE Sodium citrate, 10 mmol/L,
pH 6.8
Mouse FFPE Sodium citrate, 10 mmol/L,
pH 6.8
Mouse Cold acetone on
cryosection
NA
Mouse Cold acetone on
cryosection
NA
Mouse Cold acetone on
cryosection
NA
Mouse Cold acetone on
cryosection
NA
AEC, aminoethylcarbazole; DAB, diaminobenzidine; FFPE, formalin-fixg of CLF-1/CLC were then diluted 10-fold in sterilephosphate-buffered saline to achieve a final volume of
30 L at pH 7.4. The vehicle control was an equivalent
dilution of the hydrochloric acid and bovine serum
albumin diluent. Each animal received up to 14 doses
of CLF-1/CLC or vehicle control. We quantified endo-
toxin in the delivered reagents by the Limulus amebo-
cyte lysate (LAL) method (GenScript, Piscataway, NJ)
and determined that each animal received 2.0 EU
endotoxin per experiment. This number is considered
low and is similar to that in a published study using
intranasal administration of a recombinant protein.19
Mice were anesthetized with isoflurane in an anesthe-
sia chamber, a volume of 30 L of CLF-1/CLC or vehi-
cle control was slowly beaded onto the nares of the
mouse, and the volume was inhaled. For experiments
involving bleomycin, CLF-1/CLC or vehicle control was
administered for 2 days before bleomycin (see next
section), and then treatment was continued for up to 14
days after bleomycin injury. Animals were sacrificed at
7 or 14 days after bleomycin injury.
Intratracheal Injection of CLF-1/CLC and LIF
Animals were anesthetized with ketamine 30 mg/kg and
xylazine 6 mg/kg by intraperitoneal injection. After induc-
tion of anesthesia, an incision was made in the middle of
the neck to expose the trachea. After tracheotomy, a
sterile 18-gauge catheter was inserted. A volume of 200
L of LIF 2.5 g, PBS, or CLF-1/CLC 5 g was instilled.
Then the animal was ventilated via the catheter by means
of a small-animal ventilator (model 683; Harvard Appara-
tus, Holliston, MA). After 15 minutes, the animal was
euthanized and the lungs were inflation-fixed with 10%
neutral-buffered formalin. Lung tissue was then pro-
cessed for immunostaining with rabbit IgG directed
Target
Species of
primary antibody
Developing agent
(color)
TFR Goat AEC (red)
ospho-Stat3 Rabbit Ni-DAB (black)
-C Rabbit DAB (brown)
use neutrophils Rat DAB (brown)
et Rat DAB (brown)
xP3 Rat DAB (brown)
68 Rat Ni-DAB (black)
3 Rat Ni-DAB (black)
4 Rat Ni-DAB (black)
8 Rat Ni-DAB (black)
raffin-embedded; NA, not applicable; Ni, nickel.emistry
CN
Ph
SP
Mo
T-b
Fo
CD
CD
CD
CDagainst p-Stat3 as described below.
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and Histopathology
Male C57BL/6 mice (6 to 8 weeks old) were purchased
from the Jackson Laboratory (Bar Harbor, ME). The mice
were anesthetized with isoflurane in an anesthesia cham-
ber. Bleomycin at 3 mg/kg (standard dose)36 or 1 mg/kg
(low dose) or saline control was administered intranasally
in a volume of 30 L. Mice were sacrificed on days 1, 3,
7, 14, or 21 with pentobarbital, and the lungs were ex-
cised for histopathology, immunostaining, isolation of
RNA, and determination of collagen content. Lung tissue
was flash-frozen in liquid nitrogen or formalin-fixed and
paraffin-embedded. Routine H&E and Masson’s
trichrome staining of tissue sections was performed by
the Columbia University or the University of Pittsburgh
histology services.
Immunostaining of Human and Rodent Lung
Sections
Staining of Human Lung
Deidentified cryosections of human lung from pa-
tients with IPF or normal control subjects (histologically
normal lung distant from a tumor) were air-dried, fixed
in 2% paraformaldehyde, and rehydrated. For IHC,
sections were incubated with rabbit IgG directed
against CLF-1 (Sigma-Aldrich) or nonimmune rabbit
IgG overnight. After incubation with a biotinylated anti-
rabbit secondary antibody, color was developed using
a Vectastain universal ABC kit and diaminobenzidine
(Vector Laboratories). Sections were counterstained
with Gill’s hematoxylin (Vector Laboratories).
For immunofluorescent staining of lung, two rabbit
primary antibodies were used. First, sections were
stained using rabbit IgG directed against surfactant
protein C (SP-C). Sections were then incubated with
goat anti-rabbit Fab fragments, followed by a biotinyl-
ated anti-goat secondary antibody. CLF-1 was stained
as above. To develop the color, a rhodamine-conju-
gated donkey anti-rabbit secondary antibody was
used to stain CLF-1, and Cy5-conjugated streptavidin
was used to stain SP-C. To stain for macrophages and
CLF-1, a mouse anti-human CD68 antibody was used
in combination with rabbit anti-CLF-1. Color was devel-
oped using Alexa Fluor 488-conjugated anti-mouse
and rhodamine-conjugated anti-rabbit secondary anti-
bodies (Life Technologies-Invitrogen). Sections were
counterstained with DAPI. Images were photographed
on a Nikon TE200 microscope equipped with epifluo-
rescence. All images were processed with Adobe Pho-
toshop C5 Extended version 12.04x32 under identical
conditions, for presentation.
Staining of Rodent Lung
Conditions for staining rodent lungs are summarized in
Table 1. All bright-field images were taken with an Olym-
pus DP25 camera on an Olympus CH2 microscope.To double-stain for p-Stat3 and SP-C, a similar strat-
egy was used to that described above for human lung.
Formalin-fixed, paraffin-embedded sections were
deparaffinized, rehydrated, and exposed to EDTA an-
tigen retrieval. The first antigen was stained using rab-
bit polyclonal IgG directed against p-Stat3 (Cell Sig-
naling Technology), followed by incubation with goat
anti-rabbit Fab fragments, and then a biotinylated-anti-
goat secondary antibody. Color was developed using
a Vectastain ABC universal kit and then a Vector SG
substrate kit for a blue/gray color in the nucleus (Vector
Laboratories). After avidin-biotin blocking (Vector Lab-
oratories), sections were incubated with rabbit anti-
SP-C. After incubation with a biotinylated anti-rabbit
secondary antibody, color was developed with the
Vectastain universal ABC kit and diaminobenzidine.
Quantification of Cells in Mouse Lung Sections
Sections of mouse lungs were stained as described
Figure 1. CLF-1 expression is increased in IPF and in bleomycin injury. A:
Quantitative RT-PCR of CLF-1 mRNA normalized to peptidyl prolyl isomerase
A (PPIA) mRNA on samples obtained from lungs of patients with IPF (n 
50), compared with normal control subjects (n  49). *P  0.0001, Wilcoxon
rank sum test. B: Quantitative RT-PCR was performed on lungs from mice at
various time points after bleomycin injury (3 mg/kg). *P  0.05 versus saline
control, one-way analysis of variance. n  4 per group. Box plots indicate
median, quartiles, and range.in Table 1. A blinded reader counted the number of
tion of C
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under the 40 objective, as we have described previ-
ously.36 For each experiment, an average of 113 fields
were counted per animal. Data are presented as
means  SEM.
Sircol Assay for Acid-Soluble Collagen
After sacrificing the animals, left lungs were excised and
snap-frozen in liquid nitrogen, followed by lyophilization.
Lungs were homogenized in 0.5 mol/L acetic acid with a
protease inhibitor cocktail (Sigma-Aldrich) and mixed
gently at 4°C overnight. The homogenate was pelleted,
and the supernatant was run across a QIAshredder ho-
mogenizer column (Qiagen), as described previously.19
The Sircol assay was performed according to the manu-
facturer’s instructions. Briefly, 100 L of the lung-acetic
acid mixture was added to 1 mL of the Sirius Red reagent
and incubated for 60 minutes. The collagen-dye com-
plex was pelleted by centrifugation in a microcentri-
fuge (Eppendorf, Hamburg, Germany), and the precip-
itated material was dissolved in 0.5 mol/L NaOH.
Optical density at 540 nm (OD540) was recorded using
a microplate reader.
Total RNA Isolation from Mouse Lungs
CLF-1/CLC was administered to mice for 7 days after
Figure 2. CLF-1 expression is limited to type II alveolar epithelial cells and
(A) or IPF (B and C) human lungs. Immunostaining was localized to cells th
alveolar macrophages (red arrows). C: Staining is absent in airway epithel
cence was performed for CLF-1 (D and H, green), the type II alveolar epithel
stained with DAPI (F and J, blue). G and K: Merged samples show colocaliza
Original magnification, 400 (A–C and inset); 200 (D–K and insets).bleomycin injury (3 mg/kg) or to no-injury control mice.The mice were euthanized, and the lungs were har-
vested for RNA isolation. This RNA was used for RT-
PCR and microarray analysis as described below.
Mouse lungs were first homogenized (PolyTron; Kine-
matica) and then processed with the miRNeasy mini kit
(Qiagen, Frederick, MD) for total RNA extraction ac-
cording to the manufacturer’s instructions. Total RNA
extracted was quantified with a NanoDrop spectropho-
tometer (Thermo Fisher Scientific, Wilmington, DE),
and the integrity of the RNA samples was analyzed
using an Agilent 2100 bioanalyzer with the accompa-
nying RNA 6000 nano kit. Only RNAs with OD260/OD280 
1.8 and RIN (RNA integrity number)  8 were used for
microarray experiments.
Quantitative RT-PCR on mRNA from Mouse
Lungs
Total RNA was reverse-transcribed using an ABI high-
capacity power reverse transcription kit (Life Technolo-
gies). Primers specific for GATA3, IL-17, RORc, and PPIA
were from Qiagen. Quantitative RT-PCR was performed
using SYBR Green chemistry on an ABI 7500 system
(Applied Biosystems). Fold change was calculated by
the 2Ct method, and data were analyzed with ABI
7500 system software version 1.3.1 according to the
hages in IPF lungs. IHC for CLF-1 was performed on cryosections of normal
hologically appear to be type II alveolar epithelial cells (black arrows) and
Inset: Staining with nonimmune rabbit IgG control. D–K: Immunofluores-
arker SP-C (E, red), and the macrophage marker CD68 (I, red). Nuclei were
LF-1 with SP-C (G) and with CD68 (K). Insets (D–K): Nonimmune controls.macrop
at morp
ial cells.
ial cell mmanufacturer’s recommendations.
ulated c
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Lungs
Five hundred nanograms of the total RNA was labeled
and amplified with the Agilent Quick Amp labeling kit. The
quality of this purified cRNA was assessed using Nano-
Drop microarray measurement. The fragmented cRNA
with specific activity of 9 and a yield of 1.65 g was
hybridized to Agilent 4x44K whole mouse genome mi-
croarrays for 17 hours. The chips were washed with Agi-
lent gene expression wash buffers 1 and 2 and scanned
with an Agilent scanner.
Array images were processed using the Agilent Fea-
ture Extraction protocol version 9.5.3.37 All arrays were
cyclic-LOESS normalized using the Bioconductor pack-
age (version 2.8) as described previously.38 For statisti-
cal analysis, we applied one-way analysis of variance. A
false discovery rate of 1% was used as a cutoff for sta-
tistical significance in microarray data. Data visualization
and clustering were performed using Genomica version
3.040710,39 GeneSpring GX version 11.5.1 and Score-
genes version 1.0,40 and Spotfire Decision Site 9 (TIBCO,
Palo Alto, CA). For qRT-PCR, student’s t-test was used
and significance was defined at P  0.05. Data were
imported into the NIH DAVID bioinformatics database
version 6.7 for functional annotation and analysis for gene
enrichment.41
Statistical Analysis
Data were analyzed using SAS version 9.2 (SAS Insti-
tute, Cary, NC), as well as the R environment version
Figure 3. Expression of CNTFR and responsiveness to CLF-1 stimulation is
uninjured rat lung. Immunostaining appears to be localized to type II alve
underwent transtracheal injection of vehicle control (B), LIF (C), or CLF-1
processed for IHC for p-Stat3 (black) and SP-C (brown). In vehicle-treate
p-Stat3/SPC (black arrows) and p-Stat3/SPC (red arrows) staining w
E: Quantification of p-Stat3 cells in vehicle-treated and CLF-1-treated a
rat type II alveolar epithelial cells up to 60 minutes after CLF-1 stimulatio
representative of four independent experiments. *P  0.05 versus unstim
and Inset).2.13.1 for statistical analysis42 with confirmation of two-way analysis of variance results using Open BUGS
software version 3.2.1 for Bayesian model fitting via
Gibbs sampling and the Regression Modeling Strategy
package.43 Assay results were natural log-transformed
where indicated by analysis of residuals for normality
and subjected to one- or two-way analysis of variance.
Main effects and interactions between bleomycin and
CLF-1 were tested using maximum likelihood.
ed to type II alveolar epithelial cells. A: IHC was performed for CNTFR on
ithelial cells. Inset: Staining is absent with nonimmune goat IgG. Animals
). Animals were ventilated for 15 minutes, and the lungs were fixed and
als (B), no p-Stat3 staining was present. In LIF-treated animals (C), both
ved. After CLF-1 stimulation (D), p-Stat3 cells were limited to SP-C cells.
*P  0.0001. n  4 per group. F: Immunoblotting for p-Stat3 in primary
ensitometric analysis of p-Stat3 band intensity normalized to total Stat3,
ontrol, one-way analysis of variance. Original magnification, 400 (A–D
Figure 4. Lung histology from animals exposed to CLF-1/CLC. Animals (n
5 per group) were administered CLF-1/CLC or a vehicle control, 7 days after
bleomycin injury (3 mg/kg) or no-injury control. Animals were sacrificed,
and the lungs were removed and processed for routine histological staininglocaliz
olar ep
/CLC (D
d anim
as obser
nimals.
n. G: Dwith H&E. A: Vehicle. B: CLF-1/CLC. C: Bleomycin  vehicle. D: Bleomycin 
CLF-1/CLC. Original magnification, 100.
eomycin
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Gene Expression Profiling Shows Significantly
Increased Expression of CLF-1 in IPF Lungs
Compared with Normal Controls
To gain insight into the pathogenesis of IPF, we previ-
ously performed gene expression profiling of IPF lungs
compared with normal controls.33 Considering the top 80
up-regulated genes, we noted that CLF-1 (the CRLF1
protein product) was the only IL-6 family member that
was up-regulated in IPF samples. We validated signifi-
cantly increased expression of CLF-1 in IPF in a separate
cohort of patients. CLF-1 mRNA expression was up-reg-
ulated 6.5-fold in IPF patients (n  50), compared with
normal control subjects (n  49) (P  0.0001; Figure 1A).
We also determined whether CLF-1 expression was in-
creased in the lung after bleomycin injury (Figure 1B).
Data were natural log-transformed and subjected to one-
way analysis of variance. CLF-1 expression increased
after administration of bleomycin. Statistically significant
increases in CLF-1 expression were detected from day 7
through day 28, compared with the uninjured control (P
0.05). Thus, we found significantly increased expression
of CLF-1 both in humans and in experimental pulmonary
fibrosis.
Strong Immunoreactivity for CLF-1 Is Observed
in Type II Alveolar Epithelial Cells
and Macrophages in IPF Lungs
To determine which cell types express CLF-1 in IPF
lungs, we performed IHC for CLF-1 (Figure 2, A–C). Little
staining was observed in sections of uninjured lungs from
patients. On cryosections of IPF lungs, we observed
strong staining for CLF-1 in cells that morphologically
appear to be type II alveolar epithelial cells and macro-
phages (Figure 2, A and B). Staining for CLF-1 appeared
to be localized to the alveolar parenchyma. No staining of
airway epithelial cells in IPF was noted (Figure 2C). No
Figure 5. CLF-1/CLC promotes the accumulation of CD3 and CD68 cells
CLF-1/CLC or a vehicle control (n  5 per group) at 7 days after bleomyci
alveolar epithelial cells (A), neutrophils (B), CD3 for T cells (C), B220 for B ce
field (hpf). *P 0.05, main effects of CLF-1/CLC; †P 0.05, main effects of bl
is further described under Results).staining was seen using nonimmune rabbit IgG. To con-firm the identity of the positively staining cells in IPF
lungs, we performed double-label immunofluorescence
for CLF-1 with the type II alveolar epithelial cell marker
surfactant protein C (SP-C) (Figure 2, D–G) and the mac-
rophage marker CD68 (Figure 2, H–K). Merged images
show colocalization of CLF-1 in SP-C and CD68 cells.
These results indicate that CLF-1 expression in the lung
was localized to type II alveolar epithelial cells and mac-
rophages.
Expression of the Specific CLF-1 Receptor
CNTFR Is Localized to Type II Alveolar
Epithelial Cells
Having identified the source of CLF-1 expression, we
next turned our attention to identifying the cells in the lung
that respond to CLF-1 signaling. CLF-1 exists naturally as
a secreted heterodimer complexed with cardiotrophin-
like cytokine (CLC).34 Like other IL-6 family members,
CLF-1/CLC signals through gp130 and leukemia inhibi-
tory factor receptor  (LIFR). By IHC, we found that
LIFR was strongly expressed by multiple cell types in
IPF lungs (data not shown). Unlike other IL-6 family mem-
bers, CLF-1/CLC also requires the participation of a third
member of this complex, ciliary neurotrophic factor re-
ceptor (CNTFR), to transduce downstream signaling
events.44 We then performed IHC for CNTFR using goat
IgG specific for rat CNTFR on lung sections from unin-
jured rats (Figure 3A). We found immunostaining for
CNTFR in cells that appear morphologically to be type II
alveolar epithelial cells. No staining was detected with
nonimmune goat IgG. To determine whether cells in ro-
dent lungs are capable of mediating transmembrane sig-
naling of CLF-1/CLC, we instilled rhCLF-1/CLC, LIF, or
vehicle control into the lungs of mice and performed IHC
for p-Stat3 (Figure 3, B–D). No immunostaining for p-
Stat3 was detected in vehicle-exposed animals. In an-
imals exposed to CLF-1/CLC, immunostaining for p-
Stat3 appeared to be localized to SP-C cells only;
8.5-fold more p-Stat3 cells were quantified in CLF-1/
se lungs. IHC was performed on lungs from animals that were administered
(3 mg/kg) or no-injury control, using cell-specific markers SP-C for type II
nd CD68 for macrophages (E). Cell numbers were quantified per high-power
. Data were analyzed by two-way analysis of variance (the statistical analysisin mou
n injury
lls (D), aCLC-exposed lungs compared with vehicle controls
augme
B).
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types was unlikely to be due to insufficient access of
the cytokine to other cell types, because in animals
similarly exposed to another cytokine capable of acti-
vating the Stat3 pathway, LIF, immunostaining for p-
Stat3 was present in many cell types that were either
SP-C or SP-C.
To confirm that type II alveolar epithelial cells are ca-
pable of responding to CLF-1 in a cell-autonomous fash-
ion, we incubated primary rat type II alveolar epithelial
cells in culture with CLF-1/CLC or vehicle control for 0,
15, 30, or 60 minutes (Figure 3, F and G). By immuno-
blotting, we detected p-Stat3 in primary rat type II al-
veolar epithelial cell lysates from CLF-1/CLC stimu-
lated cultures, compared with normal controls. Taken
together, these data show that expression of CNTFR, a
specific receptor for CLF-1/CLC, is localized to type II
alveolar epithelial cells. We also found that type II
alveolar epithelial cells are preferentially stimulated by
exposure to CLF-1/CLC as measured by phosphoryla-
tion of Stat3.
Exposure of Animals to Chronic CLF-1/CLC
Administration
Because CLF-1 expression was significantly increased
Figure 6. CD4, Tbet, and Foxp3 cells accumulate in the lungs of bleom
from bleomycin-injured animals treated with vehicle control (A) or CLF-1/CL
group) (D), the Th1 marker Tbet (E), and the Treg marker Foxp3 (F) (n  3
GATA3 (G), the Th17 marker IL-17 (H), and the Tfh marker RORc (I). Sig
bleomycin injury (†P  0.05), but CLF-1/CLC treatment did not significantly
†P  0.05, main effects of bleomycin. Original magnification, 400 (A andin IPF lungs, we sought to determine whether exposureof animals to CLF-1 at high local concentrations would
cause both lung injury and fibrosis or potentiate injury in-
duced by a fibrotic stimulus such as bleomycin. To answer
this question, we exposed animals to daily intranasal ad-
ministration of CLF-1/CLC or vehicle control, with and with-
out bleomycin (Figure 4, A–D). In animals treated with ve-
hicle only, there was a mild inflammatory infiltrate without
any architectural distortion. In the CLF-1/CLC-treated ani-
mals, there was no architectural distortion, but isolated lym-
phoid aggregates were observed. In animals treated with
CLF-1/CLC or vehicle control daily for 7 days after bleomy-
cin, there was significant inflammation and architectural dis-
tortion (Figure 4, C and D). In the CLF-1/CLC-exposed an-
imals injured with bleomycin, there was greatly amplified
inflammation and tissue injury. In a second cohort of ani-
mals, we continued treatment out to 14 days after bleomy-
cin injury. In the animals exposed to CLF-1/CLC and vehicle
alone, all animals survived to 14 days. In the animals injured
with bleomycin and treated with vehicle, only one animal
died (on day 13). In contrast, in the bleomycin-injured, CLF-
1/CLC-treated animals, there was significantly increased
mortality beginning on day 7, with most animals having met
predefined criteria for euthanasia (data not shown). These
data indicate that CLF-1/CLC promotes inflammation, tissue
injury, and increased mortality in animals injured with bleo-
jured animals treated with CLF-1/CLC. IHC was performed for CD3 in lungs
C was performed for CD4 (n  5 to 7 per group) (C), CD8 (n  3 or 4 per
p). Quantitative RT-PCR was performed on lung samples for the Th2 marker
differences in gene expression for GATA3 and RORc were detected after
nt expression for GATA3, IL-17, or RORc. *P  0.05, main effects of CLF-1;ycin-in
C (B). IH
per grou
nificantmycin at 3 mg/kg.
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Animals Exposed to rhCLF-1/CLC
Because of the marked effects of CLF-1/CLC exposure
on lung histology, we performed a quantitative analysis of
cell lineages in the lungs from animals exposed to CLF-
1/CLC treatment at 7 days after bleomycin injury or un-
injured controls (Figure 5, A–E). We performed IHC for
markers of type II alveolar epithelial cells, neutrophils, T
cells, B cells, and macrophages. Cells were quantified,
and the data were natural log-transformed and subjected
to two-way analysis of variance as described under Ma-
terials and Methods. A significant increase in the number
of SP-C (Figure 5A) cells was detected after adminis-
tration of bleomycin (P 0.0001). An interaction between
CLF-1/CLC and bleomycin was present (P  0.05), but
no significant effect of CLF-1/CLC on the number of
SP-C cells was detected. Significant decreases in the
number of neutrophils (Figure 5B) were detected after
administration of bleomycin (P  0.0001). An interaction
Figure 7. CLF-1/CLC treatment of bleomycin-injured animals increases in-
flammation but decreases fibrosis. Animals were pretreated with CLF-1/CLC
for 2 days and then were administered bleomycin at 1 mg/kg (low dose).
Treatment continued daily for an additional 12 days. Animals were sacrificed,
and the lungs were removed and processed for H&E staining (A and C),
Masson’s trichrome staining (B and D), and determination of collagen con-
tent (E). A and B: Vehicle-treated, bleomycin-injured. C and D: CLF-1/CLC-
treated, bleomycin-injured. E: At 12 days after injury with low-dose bleomy-
cin or saline controls, left lungs were processed for detection of collagen by
Sircol assay. Low-dose bleomycin injury led to significantly increased colla-
gen content, compared with uninjured controls (†P  0.05), and CLF-1/CLC
led to significant reductions in collagen content at baseline and after bleo-
mycin injury (*P  0.05). Vehicle, n  6; CLF-1/CLC, n  5; bleomycin 
vehicle, n  7; bleomycin  CLF-1/CLC, n  12. Original magnification,
100.between CLF-1/CLC and bleomycin was present (P 0.05), but no significant effect of CLF-1/CLC was de-
tected on the number of neutrophils. Significant in-
creases in the number of CD3 cells (Figure 5C) were
detected in the presence of CLF-1/CLC (P  0.0005). No
interaction between bleomycin and CLF-1/CLC was de-
tected on the number of CD3 cells. At 7 days after
bleomycin administration, the number of B220 cells
(Figure 5D) detected was significantly increased (P 
0.02). No interaction between CLF-1/CLC and bleomycin
was detected. At 7 days after bleomycin and CLF-1/CLC
administration, a significant increase in the number of
CD68 cells was detected (Figure 5E). No interaction
between CLF-1/CLC and bleomycin was detected. When
the model was reanalyzed without interaction, the princi-
pal effect on the number of CD68 cells was the result of
CLF-1/CLC (P 0.05), with a borderline contribution from
bleomycin (P  0.08). Taken together, these data show
that administration of CLF-1/CLC, both in the presence
Table 2. Top 35 Probes Induced by CLF-1 versus Vehicle
Symbol Gene name
Fold
change
CXCL9 Chemokine (C-X-C motif) ligand 9 27.8
UBD Ubiquitin D 22.2
CLCA3P Chloride channel accessory 3,
pseudogene
16.6
CXCL10 Chemokine (C-X-C motif) ligand 10 12.2
GBP1 Guanylate binding protein 1,
interferon-inducible, 67kDa*
10.6
LOC667597 cDNA sequence BC023105 9.5
LOC667597 cDNA sequence BC023105 7.5
CCL2 Chemokine (C-C motif) ligand 2 5.6
CXCL11 Chemokine (C-X-C motif) ligand 11 5.5
APOL6 Apolipoprotein L, 6 5.4
CCL7 Chemokine (C-C motif) ligand 7 5.0
MAPK10 Mitogen-activated protein kinase
10
4.8
MYBPC3 Myosin binding protein C, cardiac 4.7
IFNG Interferon, gamma 4.6
GJA3 Gap junction protein, alpha 3, 46
kd
4.6
IFNG Interferon, gamma 4.6
ADAMTS19 ADAM metallopeptidase with
thrombospondin type 1 motif, 19
4.6
BC061237 cDNA sequence BC061237 4.5
ALPK2 Alpha-kinase 2 4.5
PRAMEF3 PRAME family member 3 4.4
CCL7 Chemokine (C-C motif) ligand 7 4.2
PLN Phospholamban 4.2
BC006965 cDNA sequence BC006965 4.0
KCNJ3 Potassium inwardly rectifying
channel, subfamily J, member 3
3.9
IGFBPL1 Insulin-like growth factor binding
protein-like 1
3.9
CYP1A1 Cytochrome P450, family 1,
subfamily A, polypeptide 1
3.9
TTN Titin 3.9
BC061237 cDNA sequence BC061237 3.8
FGF12 Fibroblast growth factor 12 3.7
IL12B Interleukin 12B (natural killer cell
stimulatory factor 2, cytotoxic
lymphocyte maturation factor 2,
p40)
3.7
FGF12 Fibroblast growth factor 12 3.7
CORIN Corin, serine peptidase 3.7
HAMP Hepcidin antimicrobial peptide 3.6*Includes EG:2633.
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lation of CD3 cells in the lung.
CLF-1/CLC Treatment Increases the Number of
CD4 T Cells in Bleomycin-Injured Lungs
To determine the phenotype of the T cells that accumu-
lated in response to instillation of CLF-1/CLC, we stained
lung sections from animals treated with CLF-1/CLC or
vehicle control, 7 days after bleomycin injury. We per-
Table 3. Top 35 Probes Induced by Bleomycin  CLF-1 versus
Bleomycin  Vehicle
Symbol Gene name
Fold
change
CLCA3P Chloride channel accessory 3,
pseudogene
14.4
CXCL9 Chemokine (C-X-C motif) ligand 9 11.9
CXCL11 Chemokine (C-X-C motif) ligand 11 9.5
IRG1 Immunoresponsive 1 homolog
(mouse)
7.7
IRG1 Immunoresponsive 1 homolog
(mouse)
7.6
IFNG Interferon, gamma 6.3
IFNG Interferon, gamma 5.8
GZMB Granzyme B (granzyme 2,
cytotoxic T-lymphocyte-
associated serine esterase 1)
5.8
UBD Ubiquitin D 5.6
GBP4 Guanylate binding protein 4* 5.1
CCL1 Chemokine (C-C motif) ligand 1 4.9
VAX2 Ventral anterior homeobox 2 4.8
PDCD1 Programmed cell death 1 4.7
ADAMTS20 ADAM metallopeptidase with
thrombospondin type 1 motif, 20
4.2
IL21 Interleukin 21 4.1
IDO1 Indoleamine 2,3-dioxygenase 1 4.1
GBP2 Guanylate binding protein 2,
interferon-inducible
3.9
CXCL10 Chemokine (C-X-C motif) ligand 10 3.9
CD274 CD274 molecule 3.9
IL18BP Interleukin 18 binding protein 3.8
TNFSF11 Tumor necrosis factor (ligand)
superfamily, member 11
3.8
ARG1 Arginase, liver 3.8
CCR8 Chemokine (C-C motif) receptor 8 3.8
CTLA4 Cytotoxic T-lymphocyte-associated
protein 4
3.7
DCAF12L2 DDB1 and CUL4-associated factor
12-like 2
3.6
ITLN1 Intelectin 1 (galactofuranose
binding)
3.5
NUB1 Negative regulator of ubiquitin-like
proteins 1
3.5
GBP5 Guanylate binding protein 5 3.4
NKG7 Natural killer cell group 7
sequence
3.4
NKG7 Natural killer cell group 7
sequence
3.3
IL18BP Interleukin 18 binding protein 3.2
IL12RB1 Interleukin 12 receptor, beta 1 3.2
CD4 CD4 molecule 3.2
FAM26F Family with sequence similarity 26,
member F
3.2
CNGB3 Cyclic nucleotide-gated channel
beta 3
3.2
*Includes EG:115361.formed IHC for CD3 (Figure 6, A and B) and also for CD4and CD8, with quantification of the number of positively
staining cells. Significantly increased numbers of CD4
cells (Figure 6C) were detected after administration of
bleomycin and CLF-1/CLC. For CD4 cells, an interac-
tion was detected (P  0.001), with main effects by bleo-
mycin (P  0.0001) and CLF-1/CLC (P  0.05). No sig-
nificant differences were noted in the number of CD8
cells between CLF-1/CLC-treated mice and vehicle con-
trols (Figure 6D). After bleomycin injury, CLF-1/CLC treat-
ment nearly tripled the number of both Tbet (P  0.04)
and Foxp3 cells (P  0.008) in the lung (Figure 6, E and
F). For Tbet cells, no interaction between bleomycin and
CLF-1/CLC was detected using two-way analysis of vari-
ance. Performing the two-way analysis of variance with-
out an interaction term showed a significant effect of
CLF-1/CLC (P  0.01). For Foxp3 cells, no interaction
between bleomycin and CLF-1/CLC was detected using
two-way analysis of variance. Performing the two-way
analysis of variance without an interaction term identified
significant effects of both CLF-1/CLC (P  0.04) and
bleomycin (P  0.001).
We next performed quantitative RT-PCR on RNA iso-
lated from the lungs of animals exposed to CLF-1/CLC
with and without bleomycin to determine the relative
expression of markers of other important T-helper cell
lineages. A significant effect on gene expression for
GATA3 (Figure 6G) was detected after administration
of bleomycin (P  0.01), but no interaction was de-
tected between CLF-1/CLC treatment and bleomycin.
No significant effect on gene expression for IL-17 (Fig-
ure 6H) was detected after administration of bleomycin
both in the presence and in the absence of CLF-1/CLC.
A significant effect on gene expression for the Tfh
marker RORc (Figure 6I) was detected after adminis-
tration of bleomycin (P  0.001), but no interaction was
detected between CLF-1/CLC and bleomycin. There-
fore, in the context of bleomycin-induced lung injury,
CLF-1/CLC induced the accumulation of Th1 and Treg
cells.
After Low-Dose Bleomycin, CLF-1/CLC
Treatment Decreases Collagen Deposition
The IL-6 family has been implicated in the pathogenesis
of IPF as a factor promoting the growth and survival of
fibroblasts16–18 and lung injury and fibrosis.19,20 Be-
cause we observed that CLF-1/CLC induced increased
inflammation in mouse lungs, we investigated whether
this is accompanied by a change in the accumulation of
collagen, either alone or in the context of bleomycin-
induced lung injury and fibrosis. Administration of CLF-
1/CLC in animals receiving 3 mg/kg bleomycin produced
excessive mortality for quantitative analysis of fibrosis at
14 days after injury. For these experiments, therefore, we
used a lower dose of bleomycin (1 mg/kg). Compared
with bleomycin-injured, vehicle-treated animals (Figure
7A), treatment with CLF-1/CLC again produced a more
highly cellular infiltrate with a greater degree of architec-
tural distortion compared with the vehicle controls (Figure
7B). As a qualitative analysis of collagen deposition, we
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appeared to be less blue staining in the bleomycin-in-
jured and CLF-1/CLC-treated mice compared with the
vehicle controls (Figure 7, C and D). Uninjured animals
that received 14 doses of CLF-1/CLC exhibited a similar
degree of detected collagen. We quantified the effect of
CLF-1/CLC on collagen content in the presence and ab-
sence of bleomycin. Bleomycin-injured animals treated
with vehicle exhibited a twofold increase in acid-soluble
collagen content, compared with uninjured, vehicle-
treated controls. In the comparison with vehicle-treated
controls, CLF-1/CLC treatment was associated with de-
creases in collagen content for both injured and unin-
jured vehicle-treated controls. Data were analyzed by
two-way analysis of variance. Significant differences in
mean collagen levels were detected (P  0.0002), but no
interaction between CLF-1/CLC and bleomycin was de-
tected (Figure 7E). When the model was reanalyzed with-
out interaction, significant main effects of bleomycin and
CLF-1 were detected (P 0.05). We conclude that CLF-1
treatment decreases collagen content in the lung.
Gene Expression Profiling of Lungs from
Animals Treated with CLF-1/CLC
Because we observed an increase in the number of T
cells in the lungs of CLF-1/CLC-treated mice, we hypoth-
esized that these lungs from animals exposed to CLF-1/
CLC would exhibit a gene expression profile enriched in
inflammatory pathways. To gain further insight into the
molecular mechanisms underlying the proinflammatory
and antifibrotic phenotype of CLF-1/CLC-treated animals,
we performed gene expression profiling of lungs from
animals treated with CLF-1/CLC or vehicle control, with
and without bleomycin injury. Across the four experimen-
tal groups, there were 3875 differentially expressed
genes. The top 35 genes induced by administration of
CLF-1/CLC are presented in Tables 2 and 3. Of the dif-
ferentially expressed genes, clustering by K means or-
ganized the data set into six distinct clusters (Figure 8).
The clustering indicates that the gene expression
changes were dominated by bleomycin injury. The genesclustered in cluster 5 (Figure 8), however, showed a
stepwise increase in average gene expression after CLF-
1/CLC stimulation. All of the clusters were imported into
NIH DAVID for functional annotation (Table 4).41 In clus-
ter 5, the most significantly enriched pathway of genes
belonged to the immune response (see Supplemental
Tables S1–S3 at http://ajp.amjpathol.org.) Cluster 6 was
characterized by genes exhibiting decreased expression
in response to CLF-1/CLC after bleomycin injury. In this
cluster, one of the most significantly enriched pathways
involves extracellular matrix proteins (see Supplemental
Tables S4 and S5 at http://ajp.amjpathol.org.) These data
show that, after administration of CLF-1, there was in-
creased expression of inflammatory genes and de-
creased expression of several extracellular matrix genes
in murine lungs.
Discussion
In the present study, our focus was on understanding the
biology of CLF-1 in pulmonary fibrosis. We found that
CLF-1 expression was significantly increased in IPF
lungs, compared with normal controls. We also found that
CLF-1 expression in the lung was restricted to type II
alveolar epithelial cells and macrophages. CNTFR, the
receptor for CLF-1/CLC, was localized mainly to type II
alveolar epithelial cells and to a lesser extent in airway
epithelial cells. We suggest that this pattern of CNTFR
expression mediates the responsiveness of type II alve-
olar epithelial cells to CLF-1/CLC stimulation, which we
found led to phosphorylation of Stat3 in vivo. Administra-
tion of CLF-1/CLC to mice induced a dramatic increase in
the number of T cells; in the context of bleomycin injury,
CLF-1/CLC decreased pulmonary fibrosis.
Like other members of the IL-6 family, CLF-1/CLC sig-
nals via the common gp130 pathway and can lead to
phosphorylation and activation of Stat3, ERK, and
Akt.44,45 Of its known functions, CLF-1/CLC signaling
most notably promotes the growth and survival of neu-
rons46 and the differentiation of rat metanephric mesen-
chyme into mature nephron structures.47 CLF-1 functions
Figure 8. K-means clustering identifies clusters
with changes in gene expression induced by CLF-
1/CLC administration. CLF-1/CLC or vehicle was
administered to mice with and without bleomycin.
Gene expression profiling was performed on
mouse lungs. K-means clustering was performed
using six clusters. Vertical lines represent individ-
ual animals in each experimental grouping. Each
colored line represents an individual gene. Func-
tional mapping of these gene clusters is presented
in Table 4. In clusters 1 to 4, changes in gene
expression appear to be dominated by bleomycin
injury. In cluster 5, changes in gene expression
indicate a stepwise increase in expression after
CLF-1/CLC administration, compared with control.
The genes in cluster 5 map most significantly (P
3  1012) to genes coding for inflammatory pro-
teins (Table 4). In cluster 6, genes with increased
expression after bleomycin and the vehicle exhib-
ited decreased expression with CLF-1/CLC. The
genes in cluster 6 map most significantly to genes
coding for extracellular matrix proteins (P 
0.00005).as a member of the IL-6 family. Although we did not find
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Term Count P value Fold enrichment
Cluster 1
Nucleotide binding 201 1.76  1028 2.2
ATP binding 161 3.08  1023 2.3
RNA binding 73 1.55  1014 2.7
DNA replication 28 4.30  1014 5.9
Protein transport 68 3.66  1013 2.7
Cell cycle 60 4.89  1010 2.4
Kinase 80 1.88  109 2.0
Chaperone 30 3.13  109 3.6
Cytoskeleton 67 2.57  108 2.1
DNA damage 30 1.04  106 2.8
Cluster 2
Cell adhesion 20 1.14  108 5.2
Transmembrane protein 19 4.30  108 5.0
Lectin 12 1.10  106 7.0
Immunoglobulin domain 18 2.81  106 4.0
Actin binding 13 3.43  106 5.6
Calmodulin binding 9 1.00  105 8.6
Muscle protein 7 1.10  105 13.7
Receptor 46 4.75  105 1.8
Signal anchor 14 2.58  104 3.4
Lipoprotein 17 3.37  104 2.8
Cluster 3
Transcription 131 4.78  1011 1.8
Mitochondrion 74 1.04  1010 2.3
Differentiation 52 1.62  1010 2.7
Transmembrane 297 1.80  1010 1.4
Oxidoreductase 58 8.15  1010 2.4
Activator 52 9.86  1010 2.6
Alternative splicing 254 1.21  108 1.4
Cell membrane 117 6.86  108 1.6
DNA binding 96 1.32  106 1.6
Endoplasmic reticulum 56 1.60  106 2.0
Cluster 4
Mitosis 34 1.15  1035 23.1
Cell division 37 1.70  1034 17.6
Cell membrane 60 2.82  1023 4.3
Kinetochore 15 5.01  1017 29.9
Extracellular matrix 20 1.08  1014 11.4
Glycoprotein 69 5.44  1013 2.3
Centromere 11 6.73  1013 33.4
Cleavage on pair of basic residues 19 9.73  1013 9.7
Signal 61 1.83  1012 2.5
Secreted 39 3.68  1011 3.3
Cluster 5
Cytokine 16 4.89  1013 13.9
Immune response 16 8.63  1013 13.4
Secreted 34 4.21  1011 3.7
Cell membrane 37 7.25  1011 3.3
Transmembrane 65 3.21  109 1.9
Inflammatory response 9 3.73  108 17.8
Chemotaxis 8 1.40  107 19.9
Lipoprotein 18 2.24  107 4.7
T cell 6 1.51  106 29.8
Immunoglobulin domain 14 5.57  106 4.9
Cluster 6
Extracellular matrix 8 4.57  109 29.2
Acute phase 4 3.23  106 129.4
Cell adhesion 7 5.00  106 14.3
Glycoprotein 15 1.10  105 3.2
Disulfide bond 12 5.59  105 3.8
Amyloid 3 9.50  105 194.1
HDL 3 1.95  104 137.0
Sulfation 3 7.94  104 68.5
Cytokine 4 0.001 17.5
Chemotaxis 3 0.002 37.6Clusters are depicted in Figure 8.
CLF-1 and Idiopathic Pulmonary Fibrosis 1975
AJP May 2012, Vol. 180, No. 5any difference in IL-6 expression between IPF and con-
trols (data not shown), several important studies have
implicated IL-6 or other family members in the pathogen-
esis of IPF.16–20 These findings raise the question as to
why some IL-6 family members (eg, IL-6 and oncosta-
tin-M) tend to be profibrotic, whereas CLF-1 appears to
be antifibrotic, in the context of bleomycin-induced lung
injury. Indeed, by stimulating fibroblasts directly, IL-6 is
capable of inducing fibroblast proliferation, resistance to
apoptosis, and enhanced production of extracellular ma-
trix.41–43,48 We suggest that restricted responsiveness of
CLF-1/CLC for type II alveolar epithelial cells to IL-6 and
oncostatin-M (in contrast to the more widespread respon-
siveness of other cell types, including fibroblasts) is a
likely explanation for these differences.
CLF-1 expression in the lung has been reported,49 but
the role of CLF-1 has been studied mostly in the context
of the nervous system. Humans with homozygous muta-
tions in the CLF-1 gene (CRLF1) exhibit Sohar-Crisponi
syndrome,50 a rare syndrome characterized by dysmor-
phic features, muscle contractions, scoliosis, and cold-
induced sweating. Many die in infancy with respiratory
abnormalities, but the lung disease has not been clearly
defined.51 Crlf1/ and Cntfr/ mice die on postnatal
day 1 because of a suckling defect, but no pulmonary
phenotype has been described.52,53
We have shown that delivery of CLF-1/CLC to unin-
jured lungs leads to the accumulation of CD4 T cells
that organize into aggregates, both in the presence and
in the absence of bleomycin injury. These T cells are
characterized best as Th1 (expressing CD4 and Tbet)
and Treg (expressing CD4 and Foxp3) cells. Although we
observed trends toward increased expression of IL-17 in
the CLF-1-treated animals, we did not observe any dif-
ferences in the number of neutrophils in the lung. What
could account for the accumulation of the predominantly
Th1 and Treg phenotype of lymphocytes observed in the
lungs of CLF-1-treated mice? Gene expression results
indicated that CLF-1/CLC (without bleomycin) induced a
fourfold increase in IL-12B and a fivefold increase in
IFN- in mouse lungs. Among the top 200 up-regulated
genes were 10 chemokine genes with increased expres-
sion (CCL1, CCL2, CCL3, CCL7, CCL12, CCL19, CXCL9,
CXCL10, CXCL11, and XCL1), all of which have been
implicated in the chemotaxis of T lymphocytes.54–62
CCL19 expression is particularly intriguing, because it
functions in homing of T cells to secondary lymphoid
organs,63 which may account, in part, for our observation
that T cells organized into discrete aggregates in the
lungs of CLF-1-treated mice. Whether CLF-1/CLC stimu-
lates expression and secretion of CCL19 directly in type
II alveolar epithelial cells is unknown, but CCL19 expres-
sion has been shown previously in type II alveolar epi-
thelial cells.64
We found that CLF-1/CLC-treated, bleomycin-injured
animals exhibited significant increases in both inflamma-
tion and mortality.65 To obtain an adequate number of
animals for quantitative analysis of collagen deposition,
we used a lower dose of bleomycin. At this lower dose,
we observed significantly increased inflammation in the
CLF-1/CLC-treated mice but less fibrosis. How is thisapparently antifibrotic effect of CLF-1 explained? En-
hanced inflammation in the mouse lung is often associ-
ated with increased fibrosis,20,65–69 although in certain
contexts increased inflammation may be associated with
decreased fibrosis.48,70,71
We hypothesize that the increased representation of
CD4Tbet T cells in the CLF-1/CLC-treated mice en-
riches Th1 tone in the lung and leads to an antifibrotic
microenvironment in the bleomycin-injured lung.72 Sup-
porting this hypothesis is the data set from our microarray
analysis showing increased expression of the antifibrotic
cytokine interferon IFN- in bleomycin-injured, CLF-1/
CLC-treated mice, compared with the vehicle control. In
addition, there was a twofold increase in Stat1 expres-
sion, which is necessary for IFN- signaling.73 We did not
detect any differences in gene expression of the Th2
transcription factor GATA3 or the Th2 cytokines IL-4
and IL-13.
What is the contribution of the Foxp3 T cells in the
CLF-1-treated animals? In IPF, there are reduced num-
bers of CD4Foxp3 T cells in the peripheral blood and
in the bronchoalveolar lavage of IPF patients, compared
with normal controls.74,75 Furthermore, suppression of
T-cell proliferation and activation were impaired using
Treg cells derived from IPF patients, compared with cells
isolated from healthy volunteers.74 In experimental pul-
monary fibrosis, Ccr7/ mice were protected from bleo-
mycin-induced pulmonary fibrosis.76 This protection was
associated with the formation of lymphoid aggregates in
the lung and increased numbers of CD4Foxp3CD25
cells in the lung and increased expression of indoleamine
2,3-dioxygenase (Ido1), an enzyme that is up-regulated
in dendritic cells by inflammatory stimuli, including
IFN-.77 Ido1 has been found to induce Treg differentia-
tion and proliferation.78 We found that Ido1 expression
was increased fourfold in CLF-1 and bleomycin-exposed
mice. Trujillo et al76 suggest that the presence of Treg
cells is protective against fibrosis. Taken together, these
data suggest that CD4Foxp3 cells are associated with
protection from fibrosis. The mechanism by which Treg
cells exert an antifibrotic phenotype is unknown. It is
possible that Treg cells actively suppress the proliferation
and/or profibrotic activities of other T cells (eg, Th2 cells).
Further studies will be necessary to determine the mech-
anism by which Treg cells contribute to protection from
fibrosis in humans and animals.
Other potential mechanisms that may underlie the an-
tifibrotic potential of CLF-1 include significantly increased
expression of CXCL9, CXCL10, and CXCL11, chemo-
kines that are induced downstream by several stimuli,
including IFN-.79 These chemokines signal through
CXCR3.80 Cxcr3/ mice experience exaggerated pul-
monary fibrosis, which is relieved by IFN-.80 CXCL10
and CXCL11 have also been shown to attenuate bleomy-
cin-induced pulmonary fibrosis.81–83 We note that signal-
ing through CXCR3 may be deficient in IPF.6
Whether CLF-1 expression in the lung is specific to IPF
is not known. Furthermore, the stimulus for secretion of
CLF-1 in the lung is also unknown. Localization of CLF-1
expression in hyperplastic type II alveolar epithelial cells
and the capacity of CLF-1/CLC to stimulate inflammation
1976 Kass et al
AJP May 2012, Vol. 180, No. 5in the lung suggest that CLF-1 secretion may represent a
generalized response to any lung injury. In tonsillar fibro-
blasts, CLF-1 expression is increased by proinflamma-
tory mediators IFN-, TNF-, and IL-6.49 Further studies
will be necessary to elucidate the stimuli that drive ex-
pression of CLF-1 in the lung.
In summary, we report data supporting a potentially
important antifibrotic role for CLF-1 expression in IPF. We
speculate that CLF-1 expression in the lung could be a
potentially reparative response to fibrotic lung injury that
is specific to type II alveolar epithelial cells. We suggest
that the effect of CLF-1 in the lung is likely to be complex,
involving Th1 and Treg lymphocytes and production of
cytokines (eg, IFN-) and multiple chemokines. Deter-
mining whether CLF-1 has therapeutic potential as an
antifibrotic agent will require further investigation.
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